Rallybio Corp (RLYB): Price and Financial Metrics


Rallybio Corp (RLYB): $14.47

0.01 (+0.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RLYB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RLYB Stock Price Chart Interactive Chart >

Price chart for RLYB

RLYB Price/Volume Stats

Current price $14.47 52-week high $21.00
Prev. close $14.46 52-week low $5.90
Day low $14.25 Volume 67,300
Day high $15.68 Avg. volume 90,365
50-day MA $11.82 Dividend yield N/A
200-day MA $10.29 Market Cap 464.95M

Rallybio Corp (RLYB) Company Bio


Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.


RLYB Latest News Stream


Event/Time News Detail
Loading, please wait...

RLYB Latest Social Stream


Loading social stream, please wait...

View Full RLYB Social Stream

Latest RLYB News From Around the Web

Below are the latest news stories about RALLYBIO CORP that investors may wish to consider to help them evaluate RLYB as an investment opportunity.

JMP Securities Sticks to Their Buy Rating for Rallybio (RLYB)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Rallybio (RLYB - Research Report) today and set a price target of $36.00. The company's shares opened today at $13.53.Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -7.9% and a 36.03% success rate on recommended stocks. Rallybio has an analyst consensus of Moderate Buy, with a price target consensus of $36.00.See today’s best-performing stocks on TipRanks >>Based on Rallybio's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.58 million.

Catie Powers on TipRanks | September 28, 2022

Rallybio's Thrombocytopenia Candidate Shows Rapid, Complete Elimination Of Transfused Platelets

Rallybio Corporation (NASDAQ: RLYB) announced preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212 to prevent fetal and neonatal alloimmune thrombocytopenia. The data demonstrate that one week after a single subcutaneous dose, RLYB212 could rapidly eliminate transfused HPA-1a positive platelets compared to placebo in a challenge model of a catastrophic fetal-maternal hemorrhage. Additional pharmacokinetic data suggests the opportunity for less frequent dosing. Consiste

Yahoo | September 28, 2022

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

NEW HAVEN, Conn., September 28, 2022--Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Yahoo | September 28, 2022

Rallybio to Present at the 2022 Wells Fargo Healthcare Conference

NEW HAVEN, Conn., August 31, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:10 p.m. ET in Everett, MA.

Yahoo | August 31, 2022

JMP Securities Keeps Their Buy Rating on Rallybio (RLYB)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rallybio (RLYB - Research Report), with a price target of $34.00. The company's shares opened today at $11.29.Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Madrigal Pharmaceuticals. According to TipRanks, Wolleben has an average return of -3.2% and a 45.76% success rate on recommended stocks. Currently, the analyst consensus on Rallybio is a Moderate Buy with an average price target of $34.00.See the top stocks recommended by analysts >>The company has a one-year high of $21.00 and a one-year low of $5.90.

Christine Brown on TipRanks | August 8, 2022

Read More 'RLYB' Stories Here

RLYB Price Returns

1-mo 32.51%
3-mo 91.91%
6-mo 76.03%
1-year -26.10%
3-year N/A
5-year N/A
YTD 51.68%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.541 seconds.